Neoadjuvant Therapy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

An International, Multicentre, Open-label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab After Neoadjuvant Chemotherapy Plus Durvalumab in Patients With Stage IIB-IIIB (N2) Resectable NSCLC
Conditions: Non Small Cell Lung Cancer Interventions: Drug: Adjuvant durvalumab Sponsors: ETOP IBCSG Partners Foundation; AstraZeneca AG Switzerland Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial
Conditions: Potentially Resectable ALK Positive Non-Small Cell Lung Cancer Interventions: Drug: Iruplinalkib; Procedure: surgery Sponsors: Shanghai Pulmonary Hospital, Shanghai, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials

CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
Conditions: Locally Advanced Rectal Cancer; Neoadjuvant Therapy Interventions: Drug: PD-1 antibody; Drug: Capecitabine; Radiation: Short-course radiotherapy Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
Conditions: Breast Cancer; HER2-positive Breast Cancer Interventions: Drug: Dalcilib+letrozole+HP treatment group Sponsors: Henan Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials

The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma
Conditions: Clinical IVb Stage Oral Squamous Cell Carcinomas Patients Interventions: Drug: Adebrelimab Sponsors: Hospital of Stomatology, Wuhan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations
Conditions: Resectable MMR-deficient Solid Tumors; Resectable MMR-proficient Solid Tumors Interventions: Drug: botensilimab; Drug: balstilimab Sponsors: The Netherlands Cancer Institute; Agenus Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials

Effect of Adjuvant Chemotherapy Cycles on Patients With Node-negative Gastric Cancer Following Neoadjuvant Chemotherapy
Conditions: Locally Advanced Gastric Cancer Interventions: Other: surgery Sponsors: Fujian Medical University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials

Tolerability and Efficacy of Adjuvant T-DM1 in Patients With HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents. Real-world Multicenter Retrospective-prospective Study
Conditions: Breast Cancer Interventions: Drug: T-DM1 adjuvant Sponsors: Regina Elena Cancer Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials

Seroma control in axillary lymphadenectomy with Glubran 2 ® without drain. Multicenter, prospective, randomized, clinical trial. GALA-ND study (Glubran, Axillary Lymphadenectomy, Ambulatory, No Drain)
DiscussionSeveral studies compare the use of sealant products in axillary lymphadenectomy but generally with drains. We would like to demonstrate that patients who underwent axillary lymphadenectomy could benefit from an axillary sealant without drains and reduce axillary discomfort while maintaining a good quality of life. Assessing the relationship between axillary volume, symptoms, and related risk factors can be of great help in the control of seroma in patients who received breast cancer surgery.Trial registrationClinicalTrials.gov, NCT05280353. Registration date 02 August 2022. (Source: Trials)
Source: Trials - February 22, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression
Conditions: Carcinoma, Non-Small-Cell Lung Interventions: Drug: Toripalimab Sponsors: Ruijin Hospital; Guangdong Provincial People ' s Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2024 Category: Research Source Type: clinical trials

SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
Conditions: Gastric Cancer Interventions: Drug: SOX+Tislelizumab+LDRT Sponsors: West China Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials

Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy
Conditions: Breast Cancer Interventions: Drug: Cisplatin injection and gemcitabine; Drug: Capecitabine tablets Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer Interventions: Drug: Lazertinib+Pemetrexed+Carboplatin; Drug: Lazertinib Sponsors: Yonsei University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery
Conditions: DMMR Colorectal Cancer; Anti PD-1; Immunotherapy Interventions: Drug: Tisleizumab(BGB-A317) Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2024 Category: Research Source Type: clinical trials

Neoadjuvant Immunochemotherapy for LAOSCC
Conditions: Oral Squamous Cell Carcinoma; Locally Advanced Head and Neck Carcinoma Interventions: Drug: albumin paclitaxel, cispatin, tirellizumab Sponsors: Lai-ping Zhong; Sun Yat-sen University; Fudan University; Central South University; Fujian Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials